skip to content
Detailed Quote
5i Report
Rating
B+

Review of Tecsys Inc.

JUL 16, 2024 - TCS has demonstrated strong organic growth, and it has a healthy balance sheet and a strong backlog. Its recent results came in below expectations, but long-term demand looks healthy, and its updated guidance helped to support the stock price. It trades at a premium valuation to its peers, but we feel its strength lies in its niche healthcare vertical market, and if it can continue to grow its sales pipeline and expand its margins, that its premium valuation can be justified. We are maintaining our rating of ‘B+’.

Download Report
Company Profile
Interactive Chart
Key Ratios
Earnings
Analyst Recommendations
5i Recent Questions
Q: Hello Team,

Looking at starting a new position in a few of the 12 companies tagged. Can you rank from 1 to 12 on which companies you think is the best to start a new position in. No worries on size, industry or risk, looking for capital appreciation only over the next 3 years.

Thanks again!
Read Answer Asked by Kevin on July 15, 2024
Q: Which of the above should be most positively affected by a dropping Canadian bank rate. Pls rate in most to least..
Read Answer Asked by Ron on June 04, 2024
Insiders
Share Information
News and Media
Looking for more? Sign up for a FREE 14 day trial! No credit card required

We invite you to sign up for a 14 day free trial of 5i Research!
Experience all the benefits and tools we have to offer; stock research, model portfolios, Q&A with our experts, and so much more. Join a community of like-minded investors today!